U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory B Acute Lymphoblastic Leukemia

MedGen UID:
1636080
•Concept ID:
C4684834
•
Neoplastic Process
Synonym: Refractory B-Cell Acute Lymphoblastic Leukemia

Definition

B-acute lymphoblastic leukemia that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory B Acute Lymphoblastic Leukemia

Professional guidelines

PubMed

Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
Dholaria BR, Bachmeier CA, Locke F
BioDrugs 2019 Feb;33(1):45-60. doi: 10.1007/s40259-018-0324-z. PMID: 30560413Free PMC Article
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
Papayannidis C, Derenzini E, Iacobucci I, Curti A, Paolini S, Cilloni D, Baccarani M, Martinelli G
Am J Hematol 2009 Dec;84(12):849-50. doi: 10.1002/ajh.21548. PMID: 19844989

Recent clinical studies

Etiology

Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, Xie Z, Qiao X, Jiang H, Shao J, Yang F, Ren H, Cao Q, Qian J, Zhang J, An K, Wang J, Luo C, Liang H, Miao Y, Ma Y, Wang X, Ding L, Song L, He H, Shi W, Xiao P, Yang X, Yang J, Li W, Zhu Y, Wang N, Gu L, Chen Q, Tang J, Yang JJ, Cheng C, Leung W, Chen J, Lu J, Li B, Pui CH
J Clin Oncol 2023 Mar 20;41(9):1670-1683. Epub 2022 Nov 8 doi: 10.1200/JCO.22.01214. PMID: 36346962Free PMC Article
Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
Leahy AB, Devine KJ, Li Y, Liu H, Myers R, DiNofia A, Wray L, Rheingold SR, Callahan C, Baniewicz D, Patino M, Newman H, Hunger SP, Grupp SA, Barrett DM, Maude SL
Blood 2022 Apr 7;139(14):2173-2185. doi: 10.1182/blood.2021012727. PMID: 34871373Free PMC Article
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK
Pediatr Blood Cancer 2021 Jan;68(1):e28718. Epub 2020 Oct 24 doi: 10.1002/pbc.28718. PMID: 33098744Free PMC Article

Diagnosis

Opportunities for immunotherapy in childhood acute myeloid leukemia.
Lamble AJ, Tasian SK
Blood Adv 2019 Nov 26;3(22):3750-3758. doi: 10.1182/bloodadvances.2019000357. PMID: 31770440Free PMC Article

Therapy

Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, Xie Z, Qiao X, Jiang H, Shao J, Yang F, Ren H, Cao Q, Qian J, Zhang J, An K, Wang J, Luo C, Liang H, Miao Y, Ma Y, Wang X, Ding L, Song L, He H, Shi W, Xiao P, Yang X, Yang J, Li W, Zhu Y, Wang N, Gu L, Chen Q, Tang J, Yang JJ, Cheng C, Leung W, Chen J, Lu J, Li B, Pui CH
J Clin Oncol 2023 Mar 20;41(9):1670-1683. Epub 2022 Nov 8 doi: 10.1200/JCO.22.01214. PMID: 36346962Free PMC Article
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK
Pediatr Blood Cancer 2021 Jan;68(1):e28718. Epub 2020 Oct 24 doi: 10.1002/pbc.28718. PMID: 33098744Free PMC Article
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
Dholaria BR, Bachmeier CA, Locke F
BioDrugs 2019 Feb;33(1):45-60. doi: 10.1007/s40259-018-0324-z. PMID: 30560413Free PMC Article
Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
Wilke AC, Gökbuget N
Expert Opin Drug Saf 2017 Oct;16(10):1191-1202. Epub 2017 Aug 20 doi: 10.1080/14740338.2017.1338270. PMID: 28825327
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J, Benjamin J, Nagorsen D
Expert Opin Biol Ther 2015;15(8):1093-9. Epub 2015 May 13 doi: 10.1517/14712598.2015.1041373. PMID: 25971805

Prognosis

Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK
Pediatr Blood Cancer 2021 Jan;68(1):e28718. Epub 2020 Oct 24 doi: 10.1002/pbc.28718. PMID: 33098744Free PMC Article
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
Dholaria BR, Bachmeier CA, Locke F
BioDrugs 2019 Feb;33(1):45-60. doi: 10.1007/s40259-018-0324-z. PMID: 30560413Free PMC Article

Clinical prediction guides

Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
Dholaria BR, Bachmeier CA, Locke F
BioDrugs 2019 Feb;33(1):45-60. doi: 10.1007/s40259-018-0324-z. PMID: 30560413Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...